... After reviewing data from 10 clinical studies involving 14,000 diabetic patients, the research team says the fracture risk to diabetic women is twice that of men. ...

... This finding comes as a bit of a double whammy for diabetic women, since women become more prone to fractures than men as they age, whether or not they are diabetic.

Avandia (rosiglitazone), made by GlaxoSmithKline, and Actos (pioglitazone), made by Takeda, are both thiazolidinedione (TZD) drugs, already known to produce cardiovascular side effects. Both Avandia and Actos are known to increase the risk of heart failure and are required by the US Food and Drug Administration (FDA) to carry strong label warnings. In addition, Avandia increases the risk for heart attack, a finding that has caused its sales to plummet since the knowledge became public in May 2007. ...

Study found diabetics who discontinued drug had less treatment, worse management of disease
THURSDAY, April 16 (HealthDay News) -- Many patients who stopped using the diabetes drug rosiglitazone (Avandia) due to concerns about the drug's safety received less treatment and developed higher blood glucose levels, U.S. researchers report. ...
... This study reaffirms that patients who discontinue use of rosiglitazone (Avandia)and another thiazolidinedione (TZD) called pioglitazone (Actos) are at increased risk for higher fasting blood glucose and hemoglobin A1c levels, which may increase their cardiovascular risk, cardiologists Dr. Stuart Zarich of Yale Medical School and Dr. Richard Nesto of the Lahey Clinic, wrote in an accompanying journal editorial.